HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 3, 2007, Pages 323-327

  Holmes, William C ^a,b   Bilker, Warren B ^b   Wang, Hao ^b   Chapman, Jennifer ^b   Gross, Robert ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adherence; AIDS; HIV; Quality of life

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; FEMALE; FINANCIAL MANAGEMENT; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK; SOCIAL SUPPORT; STATISTICAL SIGNIFICANCE; SUBSTANCE ABUSE; VIREMIA; VIRUS DETECTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; DEMOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHILADELPHIA; QUALITY OF LIFE; SOCIOECONOMIC FACTORS;

EID: 37349036469     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815724fe     Document Type: Article

References (42)

1. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109-2117.
2. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
3. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
4. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
5. Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L. Ann Intern Med. 2003;139:810-816.
6. Holzemer WL, Corless IB, Nokes KM, et al. Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS. 1999;13:185-197.
7. Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000;24:123-128.
8. Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386-395.
9. Wilson TE, Barron Y, Cohen M, et al. Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis. 2002;34:529-534.
10. Carballo E, Cadarso-Suarez C, Carrera I, et al. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004;13:587-599.
11. Ganz PA, Schag CAC, Kahn B, et al. Describing the health-related quality of life impact of HIV infection: findings from a study using the HIV Overview of Problems-Evaluation System (HOPES). Qual Life Res. 1993;2:109-119.
12. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824-830.
13. Kleeberger CA, Phair JP, Strathdee SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.
14. Holmes WC, Shea JA. Two approaches to measuring quality of life in the HIV/AIDS population: HAT-QoL and MOS-HIV. Qual Life Res. 1999;8:515-527.
15. Holmes WC, Shea JA. Performance of a new, HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals. Qual Life Res. 1997;6:561-571.
16. Holmes WC, Shea JA. A new HIV/AIDS-targeted quality of life (HAT-QoL) instrument: development, reliability, and validity. Med Care. 1998;36:138-154.
17. Gross R, Bilker WB, Friedman HM, et al. High level, but not low level HIV breakthrough on efavirenz-based regimens associated with poor adherence. Presented at: 22nd International Conference on Pharmacoepidemology and Therapeutic Risk Management, International Society for Pharmacoepidemiology; 2006; Lisbon.
18. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.
19. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24:385-396.
20. Cohen S, Mermelstein R, Kamarck T, et al. Measuring the functional components of social support. In: Sarason I, Sarason B, eds. Social Support: Theory, Research, and Applications. Dodrecht, The Netherlands: Martinus Nijhoff Publishers; 1987:73-94.
21. Holstad MK, Pace JC, De AK, et al. Factors associated with adherence to antiretroviral therapy. J Assoc Nurses AIDS Care. 2006;17:4-15.
22. Peretti-Watel P, Spire B, Lert F, et al. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 2006;82(Suppl 1):S71-S79.
23. Murphy DA, Marelich WD, Hoffman D, et al. Predictors of antiretroviral adherence. AIDS Care. 2004;16:471-484.
24. Heckman BD, Catz SL, Heckman TG, et al. Adherence to antiretroviral therapy in rural persons living with HIV disease in the United States. AIDS Care. 2004;16:219-230.
25. Mellins CA, Kang E, Leu C, et al. Longitudinal study of mental health and psychosocial predictors of medical treatment adherence in mothers living with HIV disease. AIDS Patient Care STDS. 2003;17:407-416.
26. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2003;16:2175-2182.
27. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765.
28. Mathews WC, Mar-Tang M, Ballard C, et al. Prevalence, predictors, and outcomes of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care STDS. 2002;16:157-172.
29. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and Pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr. 1998;18:117-125.
30. Gao X, Nau DP, Rosenbluth SA, et al. The relationship of disease severity, health beliefs and medication adherence among HIV patients. AIDS Care. 2000;12:387-398.
31. Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270-1281.
32. City of Philadelphia Department of Public Health. Philadelphia AIDS Statistical Update. Philadelphia, PA: AIDS Activities Coordinating Office; December 2005.
33. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006;118:1745-1757.
34. Weaver KE, Llabre MM, Duran RE, et al. A stress and coping model of medication adherence and viral load in HIV-positive men and women on highly active antiretroviral therapy (HAART). Health Psychol. 2005;24:385-392.
35. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18:683-688.
36. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19-S25.
37. Ingersoll K. The impact of psychiatric symptoms, drug use, and medication regimen on non-adherence to HIV treatment. AIDS Care. 2004;16:199-211.
38. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13:1763-1769.
39. Nilsson-Schonnesson L, Diamond PM, Ross MW, et al. Baseline predictors of three types of antiretroviral therapy (ART) adherence: a 2-year follow-up. AIDS Care. 2006;18:407-414.
40. Godin G, Cote J, Naccache H, et al. Prediction of adherence to antiretroviral therapy: a one-year longitudinal study. AIDS Care. 2005;17:493-504.
41. Wilson KJ, Doxanakis A, Fairley CK. Predictors for non-adherence to antiretroviral therapy. Sex Health. 2004;1:251-257.
42. van Servellen G, Chang B, Garcia L, et al. Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women. AIDS Patient Care STDS. 2002;16:269-281.